Ryan Nelson, MD
Pulmonary Disease · Bend, ORNPI 1851633143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 25.7% of the total.
Across 22 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$125
- Advanced Respiratory, Inc$75
- AstraZeneca$70
- GSK$55
- Johnson & Johnson$49
- Genentech USA, Inc.$39
- plus $73 from 3 others
What the payments were for
- Food & beverage$486100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 6 | $125 |
| Advanced Respiratory, Inc | 1 | $75 |
| AstraZeneca | 3 | $70 |
| GSK | 3 | $55 |
| Johnson & Johnson | 3 | $49 |
| Genentech USA, Inc. | 2 | $39 |
| Bayer | 2 | $39 |
| Sandoz | 1 | $20 |
| Veran Medical Technologies, Inc. | 1 | $15 |
How this compares
$486 in reported general payments places this provider in the 55th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $8,919 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $3,207 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Bend
- Jeremy FeldmanBend$456K
- Matthew HegewaldBend$94K
- Louis D'avignonBend$4K
- Kevin ShererBend$2K
- Thomas KelleyBend$2K
- Gregory BlairBend$782
- Stephen YauPortland$984K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Jordan FeinPortland$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.